Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

Shintaro Hirata, Wanying Li, Satoshi Kubo, Shunsuke Fukuyo, Yasushi Mizuno, Kentaro Hanami, Norifumi Sawamukai, Kunihiro Yamaoka, Kazuyoshi Saito, Nadine A. Defranoux, Yoshiya Tanaka

研究成果: Article

6 引用 (Scopus)

抄録

Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p 

元の言語English
ページ(範囲)1-7
ページ数7
ジャーナルModern Rheumatology
DOI
出版物ステータスAccepted/In press - 2016 3 22

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Joints
Biomarkers
Therapeutics
Joint Diseases
Nonparametric Statistics
Area Under Curve

ASJC Scopus subject areas

  • Rheumatology

これを引用

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. / Hirata, Shintaro; Li, Wanying; Kubo, Satoshi; Fukuyo, Shunsuke; Mizuno, Yasushi; Hanami, Kentaro; Sawamukai, Norifumi; Yamaoka, Kunihiro; Saito, Kazuyoshi; Defranoux, Nadine A.; Tanaka, Yoshiya.

:: Modern Rheumatology, 22.03.2016, p. 1-7.

研究成果: Article

Hirata, Shintaro ; Li, Wanying ; Kubo, Satoshi ; Fukuyo, Shunsuke ; Mizuno, Yasushi ; Hanami, Kentaro ; Sawamukai, Norifumi ; Yamaoka, Kunihiro ; Saito, Kazuyoshi ; Defranoux, Nadine A. ; Tanaka, Yoshiya. / Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. :: Modern Rheumatology. 2016 ; pp. 1-7.
@article{b10321adea8f4d7e845657cdee714ad3,
title = "Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice",
abstract = "Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34{\%} of patients had ΔmTSS >0.5 and 12{\%} had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p ",
keywords = "Biomarkers, MBDA score, Radiographic progression, Rheumatoid arthritis, TNF inhibitor",
author = "Shintaro Hirata and Wanying Li and Satoshi Kubo and Shunsuke Fukuyo and Yasushi Mizuno and Kentaro Hanami and Norifumi Sawamukai and Kunihiro Yamaoka and Kazuyoshi Saito and Defranoux, {Nadine A.} and Yoshiya Tanaka",
year = "2016",
month = "3",
day = "22",
doi = "10.3109/14397595.2016.1153449",
language = "English",
pages = "1--7",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

AU - Hirata, Shintaro

AU - Li, Wanying

AU - Kubo, Satoshi

AU - Fukuyo, Shunsuke

AU - Mizuno, Yasushi

AU - Hanami, Kentaro

AU - Sawamukai, Norifumi

AU - Yamaoka, Kunihiro

AU - Saito, Kazuyoshi

AU - Defranoux, Nadine A.

AU - Tanaka, Yoshiya

PY - 2016/3/22

Y1 - 2016/3/22

N2 - Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p 

AB - Objective: Evaluate the association between the multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) in modified total Sharp score (mTSS) over 52 weeks and disease activity scores were examined retrospectively by Spearman's rank correlation coefficient in patients (N = 83) with RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA score and 28-joint count disease activity score (DAS28) categories and associations between ΔmTSS and MBDA score categories conditional on DAS28 categories were assessed. Results: At 52 weeks, 34% of patients had ΔmTSS >0.5 and 12% had ΔmTSS >3. Strongest correlations were observed between ΔmTSS and MBDA score (r = 0.47) or DAS28 (r = 0.42) at Week 24 and for area under the curve at Week 52 (MBDA score: r = 0.44, DAS28: r = 0.41), all p 0.5 for moderate/high MBDA score (≥30) or DAS28 (>3.2) were 6.6 (p 0.5 at 52 weeks when MBDA score was ≥30 (p 

KW - Biomarkers

KW - MBDA score

KW - Radiographic progression

KW - Rheumatoid arthritis

KW - TNF inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84961863008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961863008&partnerID=8YFLogxK

U2 - 10.3109/14397595.2016.1153449

DO - 10.3109/14397595.2016.1153449

M3 - Article

C2 - 26873570

AN - SCOPUS:84961863008

SP - 1

EP - 7

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -